The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB 3235-Number: 0076

Estimated average

burden

hours per response:

4.00

1. Issuer's Identity

CIK (Filer ID Number)

Previous
Names

None

Entity Type

0001070081 PTC THERAPEUTICS INC X Corporation

Name of Issuer Limited Partnership

PTC THERAPEUTICS, INC.

Limited Liability Company

Jurisdiction of
Incorporation/OrganizationGeneral Partnership
Business TrustDELAWAREOther (Specify)

Year of Incorporation/Organization

X Over Five Years Ago

Within Last Five Years (Specify Year)

Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer

PTC THERAPEUTICS, INC.

Street Address 1 Street Address 2

100 CORPORATE COURT

City State/Province/Country ZIP/PostalCode Phone Number of Issuer

SOUTH PLAINFIELD NJ 07080-2449 9082227000

3. Related Persons

Last Name First Name Middle Name

Peltz Stuart W.

Street Address 1 Street Address 2

c/o PTC Therapeutics, Inc. 100 Corporate Court

City State/Province/Country ZIP/PostalCode

South Plainfield NJ 07080-2449

Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Miller Langon L.

Street Address 1 Street Address 2

c/o PTC Therapeutics, Inc. 100 Corporate Court

City State/Province/Country ZIP/PostalCode

South Plainfield NJ 07080-2449

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name **Boulding** Mark E.

Street Address 1 Street Address 2 c/o PTC Therapeutics, Inc. 100 Corporate Court

State/Province/Country ZIP/PostalCode City

South Plainfield NJ 07080-2449

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Baird, III William

> **Street Address 1 Street Address 2**

c/o PTC Therapeutics, Inc. 100 Corporate Court

> State/Province/Country ZIP/PostalCode City

South Plainfield NJ 07080-2449

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Jacobson Allan S.

> **Street Address 1 Street Address 2**

100 Corporate Court c/o PTC Therapeutics, Inc.

> State/Province/Country ZIP/PostalCode City

South Plainfield NJ 07080-2449

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Schmertzler Michael

> **Street Address 2 Street Address 1**

c/o Credit Suisse First Boston 11 Madison Avenue

> **State/Province/Country** ZIP/PostalCode City

New York NY 10010

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Southwell David P.

Street Address 2 Street Address 1

c/o PTC Therapeutics, Inc. 100 Corporate Court

City State/Province/Country ZIP/PostalCode

South Plainfield 07080-2449 NJ

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Goldfischer Carl

c/o Bay City Capital Fund III LP

Street Address 1 Street Address 2

750 Battery Street

ZIP/PostalCode State/Province/Country City

San Francisco CA 94111 **Relationship:** Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Carlsen Soren

Street Address 1 Street Address 2

c/o Novo A/S Krogshoejvej 41

City State/Province/Country ZIP/PostalCode

Bagsvaerd G7 DK

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Kranda Michael

Street Address 1 Street Address 2 c/o Vulcan Ventures, Inc. 505 Fifth Avenue, S., #900

City State/Province/Country ZIP/PostalCode

Seattle WA 98104

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Bolte Axel

Street Address 1 Street Address 2

c/o HBM Partners AG Limmetquai 122, 8001

City State/Province/Country ZIP/PostalCode

Zurich V8 CH

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

4. Industry Group

Agriculture Health Care Retailing
Banking & Financial Services X Biotechnology Restaurants
Commercial Banking Health Insurance Technology

Insurance Health Insurance Technology
Insurance Hospitals & Physicians Computers

Investment Banking Pharmaceuticals Telecommunications
Pooled Investment Fund Other Health Care Other Technology

Is the issuer registered as Manufacturing Travel

an investment company under the Investment Company

Real Estate Airports

Act of 1940? Commercial Lodging & Conventions

Yes No Construction Tourism & Travel Services

Other Banking & Financial Services REITS & Finance Other Travel

ther Banking & Financial Services REITS & Finance Other Travel

Business Services Residential Other

Energy Other Real Estate

Energy Conservation

Coal Mining

Electric Utilities

Environmental Services

5. Issuer Size

	Revenue Range	OR		Aggre	gate Net Asset Value Range
	No Revenues		No Aggregate Ne	et Asset Val	ue
	\$1 - \$1,000,000		\$1 - \$5,000,000		
	\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,	,000,000	
	\$5,000,001 - \$25,000,000		\$25,000,001 - \$50	0,000,000	
X	\$25,000,001 - \$100,000,000		\$50,000,001 - \$10	00,000,000	
	Over \$100,000,000		Over \$100,000,00	00	
	Decline to Disclose		Decline to Disclo	se	
	Not Applicable		Not Applicable		
6.	Federal Exemption(s) and Exclu	sion(s) Claim	ed (select all that a	pply)	
	Rule 504(b)(1) (not (i), (ii) or (ii	X Rule 505			
	Rule 504 (b)(1)(i)		Rule 506		
	Rule 504 (b)(1)(ii)		Securities Act Section 4(5)		
	Rule 504 (b)(1)(iii)		Investment Company Act Section 3(c)		
			Section 3(c)(1	1)	Section 3(c)(9)
			Section 3(c)(2	2)	Section 3(c)(10)
			Section 3(c)(3	3)	Section 3(c)(11)
			Section 3(c)(4	4)	Section 3(c)(12)
			Section 3(c)(5	5)	Section 3(c)(13)
			Section 3(c)(6	6)	Section 3(c)(14)
			Section 3(c)(7	")	
7.	Type of Filing				
X	New Notice Date of First Sale Amendment	2009-09-22	First Sale Yet to 0	Occur	
8.	Duration of Offering				
D	oes the Issuer intend this offering	g to last more	than one year?	Yes X No	
9.	Type(s) of Securities Offered (se	lect all that ap	oply)		
	Equity			Pooled In	vestment Fund Interests
	Debt			Tenant-in-	-Common Securities
X	Option, Warrant or Other Right	to Acquire Aı	nother Security	Mineral P	roperty Securities
	Security to be Acquired Upon E	xercise of Op	tion, Warrant or	Other (de	scribe)

10. Business Combination Transaction

Other Right to Acquire Security

Is this offering being made in connection with a business combination transaction, such as Yes X No a merger, acquisition or exchange offer?

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor \$0 USD

12. Sales Compensation

Recipient Recipient CRD Number X None

(Associated) Broker or Dealer X None (Associated) Broker or Dealer CRD Number X None

Street Address 1 Street Address 2

City State/Province/Country ZIP/Postal Code

State(s) of Solicitation (select all that apply)
Check "All States" or check individual States

All States Foreign/non-US

13. Offering and Sales Amounts

Total Offering Amount \$1,000,000 USD or Indefinite

Total Amount Sold \$0 USD

Total Remaining to be Sold \$1,000,000 USD or Indefinite

Clarification of Response (if Necessary):

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

2

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$0 USD Estimate Finders' Fees \$0 USD Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment

Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.

• Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
PTC THERAPEUTICS, INC.	Stuart W. Peltz	Stuart W. Peltz	President and Chief Executive Officer	2009-10-06

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.